Marshall Financial Group LLC Grows Position in Novo Nordisk A/S $NVO

Key Points

• Marshall Financial Group LLC boosted its holding in Novo Nordisk by 711.1% in Q4, buying an additional 27,782 shares to total 31,689 shares worth $1.612 million, per its SEC filing.
• Novo Nordisk beat quarterly estimates with $1.01 EPS (vs. $0.90 expected) and $12.43 billion in revenue, and it declared a $1.2751 dividend payable April 8 with an ex-dividend date of March 30.
• Recent catalysts are mixed: the FDA approved a higher‑dose Wegovy with a U.S. launch planned in April (positive), but an FDA warning letter on pharmacovigilance, patent erosion in India and competition from Eli Lilly raise regulatory and commercial risks; analysts’ consensus remains a Hold with a $65.56 price target.

Marshall Financial Group LLC grew its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 711.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,689 shares of the company's stock after purchasing an additional 27,782 shares during the period. Marshall Financial Group LLC's holdings in Novo Nordisk A/S were worth $1,612,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Martin Capital Partners LLC lifted its holdings in Novo Nordisk A/S by 53.8% in the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company's stock worth $6,524,000 after buying an additional 41,129 shares in the last quarter. Smith Chas P & Associates PA Cpas grew its stake in shares of Novo Nordisk A/S by 105.3% during the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company's stock valued at $22,497,000 after acquiring an additional 207,959 shares in the last quarter. Clifford Swan Investment Counsel LLC grew its stake in shares of Novo Nordisk A/S by 13.7% during the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company's stock valued at $17,267,000 after acquiring an additional 37,453 shares in the last quarter. Markel Group Inc. increased its position in shares of Novo Nordisk A/S by 4.9% during the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company's stock worth $131,436,000 after acquiring an additional 110,061 shares during the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. acquired a new position in shares of Novo Nordisk A/S in the third quarter worth about $1,294,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 1.5%

Shares of Novo Nordisk A/S stock opened at $36.51 on Monday. The business has a 50-day moving average price of $48.22 and a 200 day moving average price of $51.07. Novo Nordisk A/S has a fifty-two week low of $35.85 and a fifty-two week high of $81.44. The firm has a market cap of $163.00 billion, a P/E ratio of 10.52 and a beta of 0.74. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 23.63%.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves higher‑dose Wegovy (semaglutide 7.2 mg, “Wegovy HD”) with strong STEP UP trial weight‑loss results (~20.7% mean weight loss); company plans a U.S. launch in April—this supports revenue and market share recovery vs. Lilly. Reuters: Novo Nordisk wins U.S. nod for higher-dose Wegovy
• Positive Sentiment: Chinese government official expressed support for Novo Nordisk’s continued presence and market cultivation in China—political goodwill could ease market access and reimbursement discussions in a major growth market. Reuters: China expresses hopes over Novo Nordisk's presence in market
• Neutral Sentiment: Sanford C. Bernstein initiated coverage on NVO — could increase analyst attention and liquidity; impact depends on the firm’s stance and ratings (article linked). Sanford C. Bernstein Initiates Coverage on Novo Nordisk
• Neutral Sentiment: Rhythm Pharmaceuticals won an FDA approval for a rare genetic‑obesity therapy—limited overlap with Novo’s mass‑market GLP‑1 franchise, so competitive impact is minimal. Yahoo/Finance: Rhythm Grabs A New Obesity Approval
• Negative Sentiment: An FDA warning letter flagged deficiencies in Novo’s pharmacovigilance reporting for serious/unexpected adverse events for GLP‑1s (including Ozempic/Wegovy)—this raises regulatory scrutiny and potential compliance costs, which investors view negatively. Yahoo/Finance: FDA Letter Puts Novo Nordisk GLP-1 Risks And Valuation In Focus
• Negative Sentiment: Patent expiry for semaglutide in India opens the market to low‑cost generics (reports of Ozempic copies selling for ~$14) — this threatens international pricing and volume, particularly in large emerging markets. Financial Post: Ozempic Copies to Cost $14 in India
• Negative Sentiment: Competitive pressure from Eli Lilly’s next‑gen agents (retatrutide) and positive data for rivals are keeping investor concerns about market share and pricing intensity elevated. ProactiveInvestors: Lilly GLP-1 trial data and concerns
• Negative Sentiment: Semaglutide failed to show benefit in early Alzheimer’s at AD/PD 2026—this is a setback for potential label expansion beyond metabolic indications and reduces upside from new indications. Yahoo News: AD/PD 2026: semaglutide fails in early Alzheimer’s

Analyst Ratings Changes

A number of brokerages recently commented on NVO. HSBC reissued a "hold" rating and issued a $54.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. TD Cowen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 target price for the company. in a research note on Tuesday, March 10th. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. Finally, Zacks Research upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, March 10th. Four investment analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.